Literature DB >> 8553814

Revision for aseptic loosening of uncemented cups in 4,352 primary total hip prostheses. A report from the Norwegian Arthroplasty Register.

L I Havelin1, S E Vollset, L B Engesaeter.   

Abstract

From September 1987 until January 1994 the Norwegian Arthroplasty Register recorded 5,021 primary total hip replacements performed with uncemented acetabular components. We compared the survival until revision for aseptic loosening of the cup, in the 11 commonest types (n 4,352). The overall cumulative revision rate for the acetabular components was 3.2% after 5 years and 7.1% after 6 years, with large differences among the designs. With the hydroxyapatite (HA)-coated cups and the hemispheric porous-coated cups, the failure rate was less than 0.1%. Of the unthreaded hemispheric porous-coated cups, Harris-Galante and Gemini (n 626), none had been revised, and of the HA-coated cups, Atoll and Tropic (n 1,943), only 1 had been revised. For the threaded uncoated metal-backed cups, the results varied from no revisions of the PM cups (n 148) to a cumulative 6-year revision rate of 21% for the Ti-Fit (n 300). The all-polyethylene Endler cups (n 334) had a cumulative revision rate of 14%. Women and patients with inflammatory arthritis had poorer results. However, the type and the design of the cups were of far greater importance for the results than patient-related factors.

Entities:  

Mesh:

Year:  1995        PMID: 8553814     DOI: 10.3109/17453679509002301

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  8 in total

1.  Modes of failure of a threaded acetabular cup : a radiographic study with EBRA of 42 revised cups.

Authors:  Thomas Ilchmann; Severin Neher; Franz Maurer; Kuno Weise
Journal:  Int Orthop       Date:  2006-06-08       Impact factor: 3.075

2.  No bias for developer publications and no difference between first-generation trochlear-resurfacing versus trochlear-cutting implants in 15,306 cases of patellofemoral joint arthroplasty.

Authors:  Birgit Reihs; Florian Reihs; Gerold Labek; Markus Hochegger; Andreas Leithner; Nikolaus Böhler; Patrick Sadoghi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-08-24       Impact factor: 4.342

3.  Results of 3,668 primary total hip replacements for primary osteoarthritis in patients under the age of 55 years.

Authors:  Keijo T Mäkelä; Antti Eskelinen; Pekka Pulkkinen; Pekka Paavolainen; Ville Remes
Journal:  Acta Orthop       Date:  2011-10       Impact factor: 3.717

4.  Statistical analysis of arthroplasty data. II. Guidelines.

Authors:  Jonas Ranstam; Johan Kärrholm; Pekka Pulkkinen; Keijo Mäkelä; Birgitte Espehaug; Alma Becic Pedersen; Frank Mehnert; Ove Furnes
Journal:  Acta Orthop       Date:  2011-06       Impact factor: 3.717

5.  Improved results of primary total hip replacement.

Authors:  Bjørg-Tilde S Fevang; Stein A Lie; Leif I Havelin; Lars B Engesaeter; Ove Furnes
Journal:  Acta Orthop       Date:  2010-12       Impact factor: 3.717

6.  Kaplan-Meier and Cox Regression Are Preferable for the Analysis of Time to Revision of Joint Arthroplasty: Thirty-One Years of Follow-up for Cemented and Uncemented THAs Inserted From 1987 to 2000 in the Norwegian Arthroplasty Register.

Authors:  Stein Atle Lie; Anne Marie Fenstad; Stein Håkon L Lygre; Gard Kroken; Eva Dybvik; Jan-Erik Gjertsen; Geir Hallan; Håvard Dale; Ove Furnes
Journal:  JB JS Open Access       Date:  2022-02-23

7.  Total Hip Replacement in Patients with Rheumatoid Arthritis: Trends in Incidence and Complication Rates Over 35 Years.

Authors:  Owen Taylor-Williams; Charles A Inderjeeth; Khalid B Almutairi; Helen Keen; David B Preen; Johannes C Nossent
Journal:  Rheumatol Ther       Date:  2022-01-08

8.  The Nordic Arthroplasty Register Association: a unique collaboration between 3 national hip arthroplasty registries with 280,201 THRs.

Authors:  Leif I Havelin; Anne M Fenstad; Roger Salomonsson; Frank Mehnert; Ove Furnes; Søren Overgaard; Alma B Pedersen; Peter Herberts; Johan Kärrholm; Göran Garellick
Journal:  Acta Orthop       Date:  2009-08       Impact factor: 3.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.